Skip to Content
 

VICC toll-free number 1-877-936-8422

Hematologic Cancers

The Hematology Clinic is located on the second floor of The Vanderbilt Clinic and is open from Monday through Friday from 8:00 a.m. to 5:00 p.m. Our physicians see patients with hematologic malignancies, benign hematologic disorders and specialty clinics for sickle cell anemia and hemostasis and thrombosis.

Clinical Trials for Hematologic Cancers

42 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Leukemia

VICCHEM1305

04/02/2013

Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

Basic Science

Leukemia

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

Hematologic

VICCBMT1008

02/18/2010

Skin or Gut Infiltrating Foxp3+ Cells and Their Association with Acute Graft-Versus-Host Disease Severity (deidentified)

Basic Science

Hematologic

NMDPBMT0346

07/09/2003

Repository for National Donor Program (NMDP) Research Blood Samples.

Diagnostic

Leukemia

ECOGHEMEAI141

05/10/2016

Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging

Diagnostic

Hematologic

VICCBMT1426

11/10/2014

Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus

Other

Hematologic
Leukemia
Myelodysplastic Syndrome
Pediatric Leukemia

VICCPED1639

09/28/2016

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Other

Lymphoma

VICCRAD1633

04/01/2016

Prospective Observational Trial of Low-Dose Skin Electron Therapy in Mycosis Fungoides Using Rotisserie Technique

Other

Hematologic

VICCBMT15130

01/19/2016

A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

Other

Leukemia

VICCHEM14133

11/11/2015

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Other

Myelodysplastic Syndrome

VICCBMT1407

04/17/2015

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

Other

Hematologic

VICCBMT1401

08/29/2014

Prospective Outcomes of Second-Line Therapy in Acute Graft-versus-Host Study Including ECP (POSTAGE)

Other

Hematologic

VICCBMT1158

10/20/2011

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications

Other

Hematologic

VICCBMT1110

11/02/2001

Hematopoietic Stem Cell Transplantaion and Marrow Toxic Injuries (Registry)

Supportive Care

Hematologic

VICCBMT1733

10/09/2017

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

Treatment

Multiple Myeloma

VICCBMTP1785

10/19/2017

A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects with Relapsed/Refractory Multiple Myeloma

Treatment

Multiple Myeloma

VICCHEM1701

09/25/2017

Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Treatment

Hematologic

VICCHEM1757

08/11/2017

A Phase 2b Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)

Treatment

Myelodysplastic Syndrome

VICCHEM16146

08/07/2017

A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy with DNA Methyl Transferase Inhibitors

Treatment

Leukemia
Myelodysplastic Syndrome

VICCHEM1709

08/01/2017

A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Treatment

Leukemia

VICCHEM16156

07/17/2017

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Treatment

Leukemia
Myelodysplastic Syndrome

VICCHEM16136

05/10/2017

A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Treatment

Leukemia

VICCBMT16137

05/05/2017

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Treatment

Leukemia

VICCHEM16123

05/03/2017

A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia

Treatment

Hematologic
Leukemia
Lymphoma

VICCBMT1662

03/10/2017

A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease

Treatment

Hematologic

VICCBMT16110

03/10/2017

A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

Treatment

Hematologic
Leukemia
Lymphoma

VICCBMT1610

09/30/2016

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

Treatment

Leukemia
Lymphoma

VICCBMT1651

09/30/2016

Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib

Treatment

Leukemia
Multiple Myeloma

VICCHEM1621

09/16/2016

An Open-Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies

Treatment

Hematologic
Leukemia
Lung
Miscellaneous
Small Cell

VICCHEMP1615

07/21/2016

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

Treatment

Lymphoma
Miscellaneous

VICCPHI1616

06/08/2016

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Treatment

Leukemia

VICCHEM15113

05/06/2016

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

Treatment

Leukemia
Pediatric Leukemia

COGAAML1331

04/28/2016

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Treatment

Colon
Head/Neck
Lung
Lymphoma
Melanoma
Non Small Cell
Ovarian
Rectal

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

Leukemia

VICCHEM1597

02/17/2016

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

Treatment

Leukemia
Pediatric Leukemia

COGAALL1331

02/01/2016

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Treatment

Multiple Myeloma

VICCHEM15112

01/11/2016

A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications

Treatment

Multiple Myeloma

VICCHEM14131

11/17/2015

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

Treatment

Bladder
Breast
Hematologic
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Pancreatic
Urologic

VICCHEMP1558

10/09/2015

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

Multiple Myeloma

VICCHEM1526

07/01/2015

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-Refractory to Previous Therapies

Treatment

Leukemia

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Treatment

Hodgkin's Lymphoma
Leukemia, other
Lymphoid Leukemia
Multiple Myeloma
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Hematopoietic

VICCNCPED1414

04/24/2014

HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus